KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--Apr. 2, 2024-- KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that the compensation committee of KalVista's board of directors granted nine newly-hired employees inducement options to purchase an aggregate of 65,000 shares of KalVista common stock on April 1, 2024 as inducements material to each employee entering into employment with KalVista. The options were granted in accordance with Nasdaq Listing Rule 5635(c)(4).
马萨诸塞州剑桥和英格兰索尔兹伯里--（美国商业资讯）--2024年4月2日--KalVista制药公司（纳斯达克股票代码：KALV）今天宣布，KalVista董事会薪酬委员会授予九名新雇员工激励期权，于2024年4月1日购买总计65,000股KalVista普通股，作为激励措施，激励每位员工在KalVista工作。期权是根据纳斯达克上市规则5635（c）（4）授予的。
The options have an exercise price of $11.40 per share, which was equal to the closing price of KalVista common stock on the grant date. One-fourth of the options vest on the one-year anniversary of the vesting commencement date and the remainder vest in equal monthly installments over the next three years, in each case subject to the new employee's continued service with the company. Each stock option has a 10-year term and is subject to the terms and conditions of KalVista's Inducement Equity Incentive Plan and a stock option agreement covering the grant.
这些期权的行使价为每股11.40美元，等于授予日KalVista普通股的收盘价。四分之一的期权在归属开始日期一周年之际归属，其余期权在未来三年内按月等额分期归属，每种情况都取决于新员工在公司的持续服务。每个股票期权的期限为10年，并受KalVista的激励股权激励计划的条款和条件以及涵盖该赠款的股票期权协议的约束。
About KalVista Pharmaceuticals, Inc.
关于 KalVista 制药公司
KalVista Pharmaceuticals, Inc. is a pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors for diseases with significant unmet need. KalVista disclosed positive phase 3 data for the KONFIDENT trial for its oral, on-demand therapy sebetralstat in February 2024. The Company anticipates submitting a new drug application to the U.S. FDA for sebetralstat in the first half of 2024 and expects to file for approval in Europe and Japan later in 2024. In addition, KalVista's oral Factor XIIa inhibitor program represents a new generation of therapies that may further improve the treatment for people living with HAE and other diseases.
KalVista Pharmaceuticals, Inc. 是一家制药公司，专注于口服小分子蛋白酶抑制剂的发现、开发和商业化，用于有大量未满足需求的疾病。KalVista于2024年2月披露了其口服按需疗法sebetralstat的KONFIDENT试验的3期阳性数据。该公司预计在2024年上半年向美国食品药品管理局提交sebetralstat的新药申请，并预计将于2024年晚些时候在欧洲和日本申请批准。此外，KalVista的口服因子XiA抑制剂计划代表了新一代疗法，可能会进一步改善HAE和其他疾病患者的治疗。
For more information about KalVista, please visit www.kalvista.com
有关 KalVista 的更多信息，请访问 www.kalvista.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20240402778985/en/
KalVista Pharmaceuticals, Inc.
Jarrod Aldom
Vice President, Corporate Communications
(201) 705-0254
jarrod.aldom@kalvista.com
KalVista 制药有限公司
贾罗德·阿尔多姆
企业传播副总裁
(201) 705-0254
jarrod.aldom@kalvista.com
Ryan Baker
Head, Investor Relations
(617) 771-5001
ryan.baker@kalvista.com
瑞安·贝克
投资者关系主管
(617) 771-5001
ryan.baker@kalvista.com
Source: KalVista Pharmaceuticals, Inc.
资料来源：KalVista 制药公司
译文内容由第三方软件翻译。